Cannabis Stocks
OGI Stock Forecast: Deep-Value Play or Value Trap after Q2 Earnings?
Is OGI stock a buy near 52-week lows? Discover how Organigram's record harvests, BAT backing, and Sanity Group acquisition shape its late 2026 outlook.
TLRY Stock Price Forecast: Is Tilray a Buy Post-Earnings?
Analyzing the TLRY stock price after record Q3 2026 revenues and narrowing losses. Discover the impact of craft beer, ATM dilution, and rescheduling.
TCNNF Stock: Is Trulieve the Best Buy After Rescheduling?
Analyze TCNNF stock as Trulieve reports profitable Q1 2026 earnings, leverages Schedule III tax relief, and prepares to domesticate in Delaware. Read now.
IIPR Stock Analysis: Is the 13% Dividend Yield Sustainable in 2026?
Discover if IIPR stock is a buy in 2026. We analyze the 13%+ dividend yield, recent Q1 2026 earnings, the shift to secured debt, and Schedule III impact.
TLRY Stock Analysis: Is Tilray Brands a Buy in 2026?
An expert, fundamental-driven analysis of TLRY stock in 2026. Explore Tilray Brands' craft beer pivot, European medical growth, financial results, and risks.
CGC Stock: Is Canopy Growth Finally a Buy After Schedule III?
Canopy Growth (CGC) stock is in the spotlight after the historic US Schedule III decision and a major financial restatement. Here is what investors need to know.
Hexo Stock: What Happened to HEXO and Where Is It Now?
Wondering what happened to Hexo stock? Discover the history of HEXO Corp, the details of the Tilray acquisition, and how to trade its legacy assets today.